Literature DB >> 6318006

Urinary prostaglandin E2 and vasopressin excretion in essential fatty acid-deficient rats: effect of linolenic acid supplementation.

H S Hansen, B Jensen.   

Abstract

Three groups of weanling male rats were fed on a fat-free diet for 13 weeks. One group received only the fat-free diet (FF rats), the other 2 groups received the fat-free diet and a daily supplement of 2 energy% ethyl linoleate ([n-6] rats), or 2 energy% ethyl linolenate ([n-3] rats). Urinary excretion of prostaglandin E2 (PGE2), immunoreactive arginine vasopressin (iAVP), and kallikrein were determined. PGE2 was quantitated with a radioimmunoassay having 4.9% cross-reactivity with prostaglandin E3 (PGE3). After 4 weeks on the diet, water consumption and urinary iAVP excretion increased significantly in the FF rats and the (n-3) rats compared with the (n-6) rats. Urinary PGE2 excretion was the same for all 3 groups during the first 10 weeks; thereafter it decreased in FF rats and (n-3) rats compared with the (n-6) rats. There was no difference in urinary PGE2 excretion between the FF rats and the (n-3) rats, even though large differences were found in the percentage of arachidonic acid (20:4[n-6]), icosapentaenoic acid (20:5[n-3]), and icosatrienoic acid (20:3[n-9]) of total kidney fatty acids as well as of kidney phosphatidylinositol fatty acids. Fractionation of urine extracts on high performance liquid chromatography with radioimmunoassay detection indicated that (n-3) rats excreted very little PGE3, if any. Urine output followed the same pattern, as did urinary PGE2 excretion. Urinary kallikrein was estimated at week 12 only. It was found to be significantly lower in FF rats and (n-3) rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6318006     DOI: 10.1007/bf02534534

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  25 in total

1.  Biological standardization of essential fatty acids; a new method.

Authors:  H J THOMASSON
Journal:  Int Z Vitaminforsch Beih       Date:  1953

Review 2.  Prostaglandins and the kidney.

Authors:  M J Dunn; V L Hood
Journal:  Am J Physiol       Date:  1977-09

3.  Essential fatty acid-deficient rats. I. Growth and testes development.

Authors:  E Aaes-Jorgensen; G Holmer
Journal:  Lipids       Date:  1969-11       Impact factor: 1.880

4.  A comparative study on bioassay and radioimmunoassay of vasopressin in human urine.

Authors:  J D Christensen; S E Jensen
Journal:  Acta Endocrinol (Copenh)       Date:  1978-02

5.  Metabolism of prostaglandin E2 in the rat.

Authors:  K Gréen
Journal:  Biochemistry       Date:  1971-03-16       Impact factor: 3.162

6.  Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica.

Authors:  W S Powell
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

7.  Effects of topical application of fatty acids.

Authors:  U M Houtsmuller; A van der Beek
Journal:  Prog Lipid Res       Date:  1981       Impact factor: 16.195

8.  Diglyceride lipase: a pathway for arachidonate release from human platelets.

Authors:  R L Bell; D A Kennerly; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

Review 9.  Integrated actions of renal medullary prostaglandins in the control of water excretion.

Authors:  J B Stokes
Journal:  Am J Physiol       Date:  1981-06

10.  Essential fatty acid-supplemented diet decreases renal excretion of immunoreactive arginine-vasopressin in essential fatty acid-deficient rats.

Authors:  H S Hansen
Journal:  Lipids       Date:  1982-04       Impact factor: 1.880

View more
  2 in total

1.  Whole-body utilization of n-3 PUFA in n-6 PUFA-deficient rats.

Authors:  Richard P Bazinet; Holly Douglas; Stephen C Cunnane
Journal:  Lipids       Date:  2003-02       Impact factor: 1.880

2.  A lack of correlation between linoleate and arachidonate in human breast milk.

Authors:  R A Gibson; G M Kneebone
Journal:  Lipids       Date:  1984-06       Impact factor: 1.880

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.